Swixx BioPharma

Swixx Biopharma is one of the largest commercialization platforms representing the portfolio of pharmaceutical companies in those markets in which they choose not to enter or decide to exit.  Swixx Biopharma operates across multiple countries in Central and Eastern Europe, Greece, Eurasia and several CIS countries, the Middle East and Latin America.  With a presence in 45+ countries and sales expected to reach €1.3 billion in 2026, Swixx is one of the fastest-growing independent biopharma commercialization platforms. Gathering outstanding rare disease, oncology-hematology, CNS, specialty and vaccines talent under one roof, Swixx Biopharma entered 2026 with more than 1,700 employees on board.

SK Capital acquired Swixx in June 2026.